September 04, 2025 a 08:00 am
PFE: Fundamental Ratio Analysis - Pfizer Inc.
Pfizer Inc. has a robust portfolio in the biopharmaceutical sector, providing vital medicines and vaccines globally. With solid fundamentals and diversified collaborations, it maintains a strong market presence. However, the current analyst consensus suggests caution in investment.
Fundamental Rating
Pfizer's rating sits at B+, supported by strong cash flow and equity returns but offset by a high debt-to-equity ratio.
| Category | Score | Visualization |
|---|---|---|
| Overall | 3 | |
| Discounted Cash Flow | 5 | |
| Return On Equity | 4 | |
| Return On Assets | 4 | |
| Debt To Equity | 1 | |
| Price To Earnings | 2 | |
| Price To Book | 3 |
Historical Rating
Comparing current and past scores highlights the stability in Pfizer's financial health.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-09-03 | 3 | 5 | 4 | 4 | 1 | 2 | 3 |
| Previous | 0 | 5 | 4 | 4 | 1 | 2 | 3 |
Analyst Price Targets
The uniform price target from analysts suggests limited growth expectation in the near term.
| High | Low | Median | Consensus |
|---|---|---|---|
| 24 | 24 | 24 | 24 |
Analyst Sentiment
Analyst recommendations lean towards holding, indicating a cautious stance on future performance.
| Recommendation | Number | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 15 | |
| Hold | 21 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Pfizer Inc. maintains a steady financial stance, albeit with a significant debt-to-equity ratio. The consistent price target suggests limited stock movement, and the analyst consensus aligns with a "Hold" recommendation. Investors should consider the robust pipeline of biopharmaceuticals against market saturation and competitive pressures. Overall, a balanced approach with cautious optimism may be warranted given the firm's moderate growth potential.